PKA-DNAJB1
Sign in to save this workspaceDNAJB1-PRKACA · Variant type: fusion · HGVS: p.DNAJB1-PKA fusion · Fusion partner: DNAJB1
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Capivasertib | 99.0% | 1.0% | 96.48 |
| 2 | Abrocitinib | 34.2% | 65.8% | 99.50 |
| 3 | Darovasertib | 28.2% | 71.8% | 96.99 |
| 4 | Pacritinib | 17.6% | 82.4% | 88.64 |
| 5 | Defactinib | 13.8% | 86.2% | 92.68 |
| 6 | Sunitinib | 12.3% | 87.7% | 91.73 |
| 7 | Pralsetinib | 10.3% | 89.7% | 93.43 |
| 8 | Upadacitinib | 9.2% | 90.8% | 97.98 |
| 9 | Fedratinib | 9.2% | 90.8% | 96.21 |
| 10 | Canertinib | 9.0% | 91.0% | 96.49 |
| 11 | Mitapivat | 7.8% | 92.2% | 100.00 |
| 12 | Rabusertib | 7.5% | 92.5% | 98.74 |
| 13 | Quizartinib | 7.5% | 92.5% | 99.50 |
| 14 | Tucatinib | 5.9% | 94.1% | 99.75 |
| 15 | Leniolisib | 5.7% | 94.3% | 100.00 |
| 16 | Gilteritinib | 5.5% | 94.5% | 88.97 |
| 17 | Repotrectinib | 5.0% | 95.0% | 84.21 |
| 18 | Avapritinib | 4.7% | 95.3% | 97.73 |
| 19 | Gedatolisib | 4.4% | 95.6% | 99.75 |
| 20 | Erlotinib | 4.1% | 95.9% | 99.75 |
| 21 | Ripretinib | 4.0% | 96.0% | 92.95 |
| 22 | Remibrutinib | 2.9% | 97.1% | 99.50 |
| 23 | Neratinib | 2.6% | 97.4% | 93.18 |
| 24 | Selumetinib | 2.6% | 97.4% | 100.00 |
| 25 | Zanubrutinib | 2.3% | 97.7% | 98.24 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Capivasertib | 99.0% | — | — |
| Abrocitinib | 34.2% | — | — |
| Darovasertib | 28.2% | — | — |
| Pacritinib | 17.6% | — | — |
| Defactinib | 13.8% | — | — |
| Sunitinib | 12.3% | — | — |
| Pralsetinib | 10.3% | — | — |
| Upadacitinib | 9.2% | — | — |
| Fedratinib | 9.2% | — | — |
| Canertinib | 9.0% | — | — |
| Mitapivat | 7.8% | — | — |
| Rabusertib | 7.5% | — | — |
| Quizartinib | 7.5% | — | — |
| Tucatinib | 5.9% | — | — |
| Leniolisib | 5.7% | — | — |
| Gilteritinib | 5.5% | — | — |
| Repotrectinib | 5.0% | — | — |
| Avapritinib | 4.7% | — | — |
| Gedatolisib | 4.4% | — | — |
| Erlotinib | 4.1% | — | — |
| Ripretinib | 4.0% | — | — |
| Remibrutinib | 2.9% | — | — |
| Neratinib | 2.6% | — | — |
| Selumetinib | 2.6% | — | — |
| Zanubrutinib | 2.3% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.3ms